Oncologie gains rights to Mologen's lefitolimod

Mologen AG (Xetra:MGN) granted Oncologie Ltd. (Cayman Islands) exclusive, global co-development rights and rights to develop, manufacture and commercialize lefitolimod (MGN1703) in China, Hong Kong, Macao, Taiwan and Singapore. Mologen said the co-development portion of the deal will include leverage "novel biomarker plans from Oncologie."

Mologen will receive €3 million ($3.7 million) upfront and €2 million ($2.5 million) in an equity investment. Mologen is eligible for more than €100 million ($124 million) in milestones, plus double-digit royalties...